



**HA TECH**  
BioPharma & Diagnostics



PCR-Based Platforms  
Rapid Test Kits  
Equipment  
Pharmaceutical & Biologics

**Superior Detection for a Safer World**

[ha-tech-ltd.com](http://ha-tech-ltd.com)

# Excellence through Research and Development of Innovative Biotechnology

HA TECH is an Australian based Company, developing & delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company is making long-term investments to develop pharmaceutical products and medical technologies/ devices to address major health problem in Australia and globally.



## HA TECH is looking to change the industry status quo.

As members of the global healthcare community, HA TECH focuses on reducing the burden of disease with our products and development of novel technologies.

HA TECH aims to be inclusive and make diagnostic products that are accessible and only require basic

laboratory equipment rather than restricting the use of kits to own brand equipment.

We value Science with our company run with an emphasis on researchers leading development.



# HA TECH became a winner of the 2022 Premier's NSW Export Awards!

The 2022 NSW Premier's Export Awards ceremony was held at Town Hall building by the Export Council of Australia.

"It has been an exciting Journey for the HA Tech team. We would have never imagined receiving this award 3 years ago, when our organisation consisted of only two staff members working in a shared research facility. Since then, we have created over 100 jobs, exported our products to over 25 countries, and have more than 30 products in the pipeline. This award means a lot for all our hardworking colleagues. Thank you, NSW Government and Export Australia, for organising this fantastic event!", said Abdullah Mahmud, Executive Chairman of HA Tech, in an accompanying speech.



This is a major milestone for the HA Tech and the R&D team is overjoyed to be able to contribute to HA Tech's glorious recognition.

HA Tech thanks the Export Council of Australia and NSW Government for this recognition and congratulates the winners in other categories for their outstanding achievements.



## HA TECH Departments

HA TECH is dedicated to advancing global healthcare through innovation and quality. We specialise in two key areas: Diagnostic Products and Biosimilar Products.

**Diagnostic Products** division includes rapid antigen/antibody tests (RATs) and nucleic acid tests (NATs), empowering timely and accurate detection of multiple emerging infection diseases.

**Biosimilar Products** division focuses on providing high-quality, cost-effective alternatives to biologic therapies, enabling greater accessibility to life-saving treatments for patients worldwide.

Together, these departments embody our commitment to delivering reliable, innovative solutions that enhance healthcare delivery.



## Manufacturing Capacity per month

10 million  
Rapid (antigen/antibody)  
Tests



40 million  
RT-PCR Tests

DIAGNOSTIC PRODUCT PIPELINE

Molecular Platform (PCR Test Kit) NAT Series

Respiratory Diseases

- NAT-01: SARS-CoV-2 RT-PCR Multiplex Diagnostic Kit**  
Target: SARS-CoV-2 (COVID-19)
- NAT-02: SARS-CoV-2, Flu A/B, RSV COMBO RT-PCR Multiplex Diagnostic Kit**  
Target: SARS-CoV-2 (COVID-19), Influenza A/B and Respiratory Syncytial Virus
- NAT-09: Respiratory COMBO ADV, HMPV, PIV, HRV RT-PCR Multiplex Diagnostic Kit**  
Target: Adenovirus, Metapneumovirus, Parainfluenza Type 1, 2, 3, 4 and Rhinovirus
- NAT-13: Respiratory BACTERIA COMBO BPP, BP, CP, MP RT-PCR Multiplex Diagnostic Kit**  
Target: Bordetella pertussis, Bordetella parapertussis, Chlamydophila pneumoniae and Mycoplasma pneumoniae

STI Diseases


- NAT-17: Mpox Virus Real-Time PCR Diagnostic Kit**  
Target: Monkeypox virus and Clade differentiator
- NAT-20: Skin Ulcers (HSV1/2, VZV, TP & Mpox) RT-PCR Multiplex Diagnostic Kit**  
Target: Herpes simplex virus 1/2, Varicella zoster, Syphilis (Treponema pallidum) & Mpox
- NAT-21: Sexually Transmitted Diseases (CT, NG, MG & TV) RT-PCR Multiplex Diagnostic Kit**  
Target: Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma genitalium and Trichomonas vaginalis

Cancer Detection Panel

- NAT-19: Non-Invasive Prostate Cancer Screening RT-PCR Device (ProstaPro™)**  
Target: Prostate cancer (using 11 novel biomarkers for detection)
- NAT-16: Human Papillomavirus type (HPV) Real Time PCR (Cervical Cancer Detection)**  
Targets: (Type 16, 18, 45, 31, 33, 35, 39, 52, 51, 56, 58,59, 66, 68) L1 genes and (Types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) (E6/E7 genes for early Detection of HPV cancer)


Mosquito Born Diseases

- NAT-03: Dengue, Chikungunya and Zika Combo RT PCR Multiplex Diagnostic Kit**  
Target: Dengue, Chikungunya and Zika Fever
- NAT-10: Dengue 1-4 (sub-types) RT PCR Multiplex Diagnostic Kit**  
Target: Dengue Fever Subtype 1-4
- NAT-05: Malaria RT PCR Multiplex Diagnostic Kit**  
Target: Malaria Fever



Automated PCR Result Interpretation (Software)

LUMEA™, our newly developed laboratory management platform that redefines PCR result analysis. With its lightning-fast, one-click analysis capability, LUMEA delivers accurate PCR interpretations in seconds, eliminating human error and transforming laboratory efficiency. Seamlessly integrated with all our molecular PCR-based test kits, LUMEA is offered as a complimentary feature, making advanced diagnostics accessible. Designed to meet the future needs of modern laboratories and regulatory requirements, ensuring secure and reliable data management.



| Well Data |                         |     |     |     |       |     |
|-----------|-------------------------|-----|-----|-----|-------|-----|
| Well      | Result                  | HEX | FAM | CY5 | CY5_5 | ROX |
| A1        | Positive                | 1.2 | 2.3 | 1.8 | 2     | 1.9 |
| B1        | Negative                | 0   | 0.1 | 0   | 0.1   | 0.1 |
| C1        | PRESUMPTIVE-INFLUENZA-B | 0.1 | 0   | 0   | 0     | 0   |

# Self-test kit/Point of Care Test kit (Antigen/Antibody)

## RAT series


### Respiratory Diseases

**RAT-01: SARS-CoV-2 Rapid Antigen Test Kit**  
Target: SARS CoV-2 (Covid-19)

**RAT-03: SARS CoV-2 & Influenza A/B Combo Rapid Antigen Test Kit**  
Target: SARS CoV-2 (Covid-19), Influenza A/B

**RAT-13: RSV/SARS CoV-2, Influenza A/B/ HMPV/PIV1/2/3 Rapid Antigen Test Kit**  
Target: SARS CoV-2, Influenza A/B, Respiratory Syncytial Virus, Adenovirus, Human Pneumonia, Parainfluenza 1/2/3.

**RAT-19: SARS CoV-2, Influenza A/B & RSV**  
Target: SARS CoV-2 (Covid-19), Influenza A/B and Respiratory Syncytial Virus.




### Blood Borne Diseases (STI's/Mosquito borne)

**RAT-02: Malaria P.f./Pan Rapid Antigen Test Kit**  
Target: Malaria

**RAT-06: Dengue Antigen (NS1) & Antibody (IgG,IgM) Test Kit**  
Target: Dengue Antibodies and NS1 Antigens

**RAT-09: HIV1/2 Ab/Ag & TP Combo Rapid Test Kit**  
Target: HIV1/2 Antibodies & p24 Antigen and TP

**RAT-12: HIV/HBsAg/HCV Combo Rapid Test Kit**  
Target: HIV1/2 Antibodies, Hepatitis B Antigens and Hepatitis C Antibodies



### Urine Based Test (Fertility Hormone / UTI)

**RAT-04 High Precision Mid-Stream Pregnancy Test**  
Target: Pregnancy

**RAT-10 Menopause (FSH) Test Kit**  
Target: Menopause marker

**RAT-11 Ovulation (LH) Test Kit**  
Target: Ovulation marker

**RAT-15 Rapid UTI Urine Test (Self-Test/POC)**  
Target: ASC, GLU, BIL, KET, SG, BLO, pH, PRO, URO, NIT, LEU (11 targets)

### Swab-based STI:

**RAT- 14 Gonorrhoea/Chlamydia Combo Rapid**  
Target: Gonorrhoea Antigen + Chlamydia Antigen

## PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT PIPELINE

At HA Tech, our Biotherapeutics division is at the forefront of innovation, actively developing a range of biologics. Among our notable advancements, we are proud to announce the development of biosimilar products including Insulin Glargine, Aspart, Degludec, and Semaglutide.

As we strive to enhance patient care through our commitment to scientific excellence, we are excited to share that we anticipate receiving regulatory approval for our first biological product, Insulin Glargine, by the end of 2025. At HA TECH we strive to:

- Deliver quality products to improve patient outcomes and advance the potential of modern healthcare.
- Advance the treatment of diabetes through the development of innovative and biosimilar antidiabetic drugs
- Address the shortfalls in supply for globally dependent medications.
- Combine cutting-edge research, state-of-the-art manufacturing, and rigorous clinical testing to create effective, safe, and accessible solutions for patients worldwide.



### Biological Products

| Product                                                   | Code           | Dosage Forms                                    | Activity                                                                    |
|-----------------------------------------------------------|----------------|-------------------------------------------------|-----------------------------------------------------------------------------|
| <b>Zenvia™ (100 IU/mL) (Insulin glargine-yfgn)</b>        | <b>INS-G</b>   | • 10 mL multi-dose vial<br>• 3 mL prefilled pen | Interchangeable biosimilar insulin glargine. Substitutes Lantus.            |
| <b>Lifora™ (100 IU/mL) (Insulin aspart-szjj)</b>          | <b>INS-L</b>   | • 10 mL multi-dose vial<br>• 3 mL prefilled pen | Interchangeable biosimilar insulin aspart. Substitutes Novolog.             |
| <b>GLP-1 (Semaglutide injection, 0.5 mg /1 mg / 2 mg)</b> | <b>GLP-1 S</b> | • 3 mL prefilled pen                            | Interchangeable biosimilar semaglutide. Substitutes Ozempic. (0.5, 1, 2 mg) |

### Blood Plasma Products

| Product                                  | Indications                                                                                                                            |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>Albumin</b>                           | Shock, burns, adult respiratory distress syndrome, cardiopulmonary bypass surgery                                                      |
| <b>Intravenous Immunoglobulin (IVIG)</b> | Primary immunodeficiency, autoimmune disorders, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura |
| <b>Coagulation Factors (VIII, IX)</b>    | Hemophilia and other clotting disorders                                                                                                |
| <b>Alpha-1 Antitrypsin</b>               | Genetic COPD due to antitrypsin deficiency                                                                                             |
| <b>Other Plasma Proteins</b>             | Various medical uses                                                                                                                   |



## Superior Detection for a Safer World



Unit 2/3 Packard Avenue  
Castle Hill, NSW 2154  
Sydney, Australia

☎ +61 (0)404 631 485

✉ [info@ha-tech-ltd.com](mailto:info@ha-tech-ltd.com)



[ha-tech-ltd.com](http://ha-tech-ltd.com)



Scan Brochure



Follow Us!